Application of Saccharomyces boulardii in combination with sulfasalazine in ulcerative colitis patients demonstrates significant effectiveness

Table 1 Baseline data comparison

Characteristic	Control (n = 63)	Observation (n = 64)	t/χ2	P value
Gender	-	-	0.065	0.797
Male	35	37	-	-
Female	28	27	-	-
Age (years), mean ± SD	44.27 ± 9.63	43.86 ± 9.87	0.236	0.813
BMI (kg/m²)	23.59 ± 1.86	24.11 ± 1.74	1.627	0.106
Duration (years), mean ± SD	2.65 ± 0.84	2.72 ± 0.81	0.478	0.633
Severity	-	-	0.411	0.521
Mild	25	29	-	-
Moderate	38	35	-	-

BMI: Body mass index.

Table 2 Clinical efficacy comparison

Group	n	Complete remission	Effective	Ineffective	Total effective rate (%)
Control	63	20	30	13	79.37%
Observation	64	27	33	4	93.75%
χ2	-	-	-	-	5.666
P value	-	-	-	-	0.017

Table 3 Comparison of symptom improvement (days), mean ± SD

Symptom	Control (n = 63)	Observation (n = 64)	t	P value
Abdominal pain	11.47 ± 2.15	8.35 ± 1.96	8.548	< 0.001
Diarrhea	11.04 ± 2.47	8.62 ± 1.85	6.255	< 0.001
Rectal bleeding	8.93 ± 1.64	6.32 ± 1.07	10.638	< 0.001
Fever	7.68 ± 1.42	5.43 ± 1.15	9.820	< 0.001
Mucosal healing	9.63 ± 1.86	6.12 ± 1.29	12.373	< 0.001

Table 4 Comparison of adverse reaction occurrences

Adverse reaction	Control (n = 63)	Observation (n = 64)	χ2	P value
Nausea/vomiting	2	2	-	-
Decreased appetite	2	2	-	-
Indigestion	1	1	-	-
Gastric burning sensation	1	2	-	-
Total occurrence rate (%)	9.52%	10.94%	0.069	0.792